Stock Events

Stock Events

biote 

$1.35
0
-$0.2-12.9% Friday 04:00

Statistics

Day High
1.35
Day Low
1.34
52W High
-
52W Low
-
Volume
2,820
Avg. Volume
-
Mkt Cap
43.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
0.04
0.1
0.16
0.22
Expected EPS
0.0475
Actual EPS
N/A

Financials

1.6%Profit Margin
Profitable
2021
2022
2023
2024
394.38MRevenue
6.31MNet Income

Analyst Ratings

$2.25Average Price Target
The highest estimate is 2.50.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BTMD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the hormone replacement therapy market, directly competing with Biote's bioidentical hormone replacement therapy offerings.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio in healthcare, including hormone therapy products that compete with Biote's solutions.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on innovative biotechnologies and medical solutions that overlap with Biote's hormone therapy treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, known for its biopharmaceutical products, competes in the same biotech and healthcare sectors as Biote.
Merck
MRK
Mkt Cap214.76B
Merck operates in various healthcare segments, including hormone-related therapies, making it a competitor to Biote.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb's diverse pharmaceutical products place it in direct competition with Biote, especially in the biotech-driven therapy space.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries specializes in generic and specialty medicines, including hormone therapies that compete with Biote's offerings.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk's focus on hormone replacement therapies, particularly in the diabetes and obesity areas, positions it as a competitor to Biote.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in biopharmaceuticals that target various medical conditions, competing with Biote in the broader biotech healthcare market.

About

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Show more...
CEO
ISIN
US0906831039

Listings

XNAS
US
BTMD
BOATS
BOATS
BTMD.BOATS

0 Comments

Share your thoughts

FAQ

What is biote stock price today?▼
The current price of BTMD.BOATS is $1.35 USD — it has decreased by -12.9% in the past 24 hours. Watch biote stock price performance more closely on the chart.
What is biote stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange biote stocks are traded under the ticker BTMD.BOATS.
What is biote market cap?▼
Today biote has the market capitalization of 43.56M
When is the next biote earnings date?▼
biote is going to release the next earnings report on May 12, 2026.
What were biote earnings last quarter?▼
BTMD.BOATS earnings for the last quarter are 0.06 USD per share, whereas the estimation was 0.04 USD resulting in a +50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is biote revenue for the last year?▼
biote revenue for the last year amounts to 394.38M USD.
What is biote net income for the last year?▼
BTMD.BOATS net income for the last year is 6.31M USD.
When did biote complete a stock split?▼
biote has not had any recent stock splits.